所有图片(1)
别名:
Arg34, Lys26-[Nε(γ-Glu[Nα-hexadecanoyl])]-GLP-1[7-37], H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]-Lys-α-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH, HAEGTFTSDVSSYLEGQAA-N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]K-EFIAWLVRGRG, NN2211
经验公式（希尔记法）:
C172H265N43O51
推荐产品
质量水平
检测方案
≥95% (HPLC)
形式
(Powder or Lyophilized powder or film)
颜色
white to off-white
储存温度
-10 to -25°C
生化/生理作用
Liraglutide (NN2211) is a glucagon-like peptide-1 (GLP-1)-based incretin mimetic (cAMP stimulation EC50 = 61 nM vs 55 nM with GLP-1(7-37) using human GLP-1 receptor-expressing BHK cells), where GLP-1(7-37) sequence is modified with a Lys34-to-Arg substitution and a γ-Glu-C16 acylation on Lys26 for enhanced in vivo stability (plasma t1/2 in pigs post s.c. = 14 h vs 1.2 h with GLP-1(7-37)) and efficacy against type 2 diabetes and obesity (400 μg/kg/day s.c. in rats; 100-200 μg/kg bid or single 50-200 μg/kg i.v. in rats; 100 μg/kg bid or single 30-1000 μg/kg s.c. in mice; 2 μg/kg i.v. or 3.3 μg/kg/day s.c. in pigs).
警示用语：
Warning
危险声明
危险分类
Repr. 2
WGK
WGK 3
法规信息
新产品
Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats
Molecular Medicine Reports, 18(2), 2449-2457 (2018)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice
American Journal of Physiology. Endocrinology and Metabolism, 283(4), E745-E752 (2002)
GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway
Mediators of Inflammation, 2018, 3601454-3601454 (2018)
29953740
Basic and Clinical Pharmacology and Toxicology, 123(6), 704-713 (2018)
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs
European Journal of Pharmacology, 451(2), 217-225 (2002)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门